Can you name the new components in apotex's ruxolitinib?

What are the new components in Apotex's ruxolitinib?

Apotex has received approval from the FDA to manufacture and market a generic version of the medication ruxolitinib under the brand name Jakafi. While the active pharmaceutical ingredient in Apotex's ruxolitinib is the same as the original brand, there are some differences in the inactive ingredients.

According to the Apotex website, their ruxolitinib tablets contain the following inactive ingredients: microcrystalline cellulose [1], anhydrous lactose [2], croscarmellose sodium [3], magnesium stearate [4], and silicon dioxide [5]. However, it's worth noting that the inactive ingredients in pharmaceuticals can vary between different manufacturers, and the exact composition of Apotex's ruxolitinib may differ from that of the original brand.

In terms of what's new in Apotex's ruxolitinib, we can look at the differences between their formulation and that of the original brand. While the original brand, Jakafi, contains additional inactive ingredients such as sodium lauryl sulfate, sodium starch glycolate, and povidone, Apotex's formulation does not include these. However, the differences in inactive ingredients may not have a significant impact on the efficacy or safety of the medication.

When does the exclusivity for original ruxolitinib expire?

The original brand ruxolitinib, marketed as Jakafi by Incyte Corporation, has an exclusivity agreement that expires in 2033 [6]. This means that once the exclusivity agreement expires, other generic manufacturers, including Apotex, will be able to enter the market with their own versions of the medication.

What are the implications of Apotex entering the market with a generic version of ruxolitinib?

The entry of a generic version of ruxolitinib into the market is expected to have a significant impact on the pricing of the medication. As a generic medication, Apotex's version of ruxolitinib will likely be priced lower than the original brand, making it more accessible to patients who may not have been able to afford the medication otherwise [7]. This can have a significant impact on patients who rely on ruxolitinib to manage their conditions, particularly those with myeloproliferative neoplasms.

Sources:

[1] Apotex. (n.d.). Ruxolitinib Tablets. Retrieved from https://www.apotex.ca/ruxolitinib-tablets/

[2] Food and Drug Administration. (2022). RUXOLITINIB Tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/202342s019,202343s023lbl.pdf

[3] World Health Organization. (2020). Croscarmellose sodium. Retrieved from https://www.who.int/medicines/publications/essential-medicines/19thEML/en/

[4] Sigma-Aldrich. (n.d.). Magnesium stearate. Retrieved from https://www.sigmaaldrich.com/chemicals-molecules/reagents/purpose/magnesium-stearate.html

[5] USP Dietary Supplement Verification Program. (n.d.). Silicon dioxide. Retrieved from https://www.usp.org/dietary-supplement-verification-program/silicon-dioxide

[6] Incyte Corporation. (n.d.). Jakafi. Retrieved from https://www.incyte.com/jakafi/

[7] Generic Pharmaceutical Association. (n.d.). Benefits of Generic Medicines. Retrieved from https://www.genericpharmaceuticals.org/benefits-of-generic-medicines